Trial Profile
AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms COTTONWOOD
- Sponsors Roche
- 28 Mar 2024 This study has been discontinued in Portugal, according to European Clinical Trials Database record.
- 30 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 27 Oct 2023 This trial has been discontinued in Hungary (Global end date: 29 Sep 2023).